Reprogramming Immunity: How CCR5 Blockade Could Redefine Cancer Therapy

from Rx for Biotech · host Podcast Host Chris Leidli

In this podcast episode, Dr. Jay Lalezari, CEO of CytoDyn Therapeutics, discusses the company's progress in developing a novel immunotherapy that targets the CCR5 receptor, one of the master immune cell regulators. Jay reviews some of the early clinical data with leronlimab, a first-in-class investigational monocolonal antibody that targets the CCR5 receptor and is being studied in metasatic triple-negative breast cancer and colorectal cancer.

Episode metadata supplied by the publisher feed · Published Oct 14, 2025

Embed this episode

Attribution link and audio player

NOW PLAYING

Reprogramming Immunity: How CCR5 Blockade Could Redefine Cancer Therapy

0:00 29:00

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

Wild WinsDay Wild WinsDay Pump the hump with WILD WINSday 🐪💪: Your 3-minute weekly video boost for leadership, sales, marketing, and business breakthroughs to WIN the day!

Frequently Asked Questions

How long is this episode of Rx for Biotech?

This episode is 29 minutes long.

When was this Rx for Biotech episode published?

This episode was published on October 14, 2025.

Can I download this Rx for Biotech episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!